Zonisamide effective for weight loss in women

Kim, Caroline S.
August 2003
Journal of Family Practice;Aug2003, Vol. 52 Issue 8, p600
Academic Journal
The article discusses research on the efficacy of zonisamide drug for weight loss in women. This drug is also used for treating people with epilepsy. Conducted to assess weight loss in sixty obese adults, the study was implemented in two phases. The zonisamide group lost significantly more weight than the placebo group in the initial phase of the clinical trial. Also reported were the zonisamide group's improvements in health, work, mobility and activities of daily living. Commentators of this research said that zonisamide was well-tolerated in obese female patients.


Related Articles

  • Ephedra and ephedrine: Modest short-term weight loss, with a price. Worley, Carl; Lindbloom, Erik // Journal of Family Practice;Jul2003, Vol. 52 Issue 7, p518 

    Products containing ephedrine and ephedra promote a 0.6-1.0 kg/mo weight loss over 2 to 6 months. However, the impact of these products on long-term weight loss or athletic performance is uncertain. Their use is associated with a 2- to 3-fold higher rate of psychiatric symptoms, autonomic...

  • Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in Children. Sharma, R. K.; Collipp, P. J.; Rezvani, I.; Strimas, J.; Maddaiah, V. T.; Rezvani, E. // Clinical Pediatrics;Mar1973, Vol. 12 Issue 3, p145 

    A double-blind study comparing the safety and efficacy of 42-548, a new, synthetic tricyclic appetite suppressant, with a placebo was started with 116 obese adolescent patients. All patients received a fixed daily dose of one tablet, one hour before the noon meal, for 12 weeks. A reduced caloric...

  • Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Smith, Steve R.; Aronne, Louis J.; Burns, Colleen M.; Kesty, Nicole C.; Halseth, Amy E.; Weyer, Christian // Diabetes Care;Sep2008, Vol. 31 Issue 9, p1816 

    OBJECTIVE -- To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS-- In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were...

  • Effect of milnacipran on body weight in patients with fibromyalgia. Arnold, Lesley M.; Palmer, Robert H.; Hufford, Michael R.; Wei Chen // International Journal of General Medicine;2012 Part 2, Vol. 5, p879 

    Background: The purpose of this study was to evaluate the effects of milnacipran on body weight in patients with fibromyalgia. Methods: Analyses were conducted in the following groups: patients from three double-blind, placebo-controlled milnacipran trials (3 months, n = 2096; 6 months, n =...

  • Review: orlistat and sibutramine are modestly effective for weight loss at 1 year. R., Padwal; Li S.K.; Lou D.C. // Evidence Based Medicine;Feb2005, Vol. 10 Issue 1, p13 

    The article reports that orlistat and sibutramine are modestly effective for weight loss at 1 year. Only trials of orlistat and sibutramine met the selection criteria. 16 Random Clinical Trials (RCTs) (11 of orlistat and 5 of sibutramine) were included. 14 RCTs (11 of orlistat and 3 of...

  • Sustained Weight Loss Following 1-y Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Smith, Steven; Klein, Eric; Burns, Colleen; Kesty, Nicole; Halseth, Amy; Weyer, Christian // Diabetes;Jun2007 Supplement 1, Vol. 56, pA88 

    In a previously reported 4 mo, randomized, placebo-controlled, dose-ranging study, treatment with the amylin analog pramlintide (120, 240, 360 µg, BID/TID) used in conjunction with lifestyle intervention (LSI) resulted in additional weight loss than observed with LSI alone. To assess the...

  • Slim Differences in Weight-Loss Plans.  // Tufts University Health & Nutrition Letter;Oct2007, Vol. 25 Issue 8, p3 

    This article presents a news brief about weight loss diets. A study performed by the Tufts-New England Medical Center analyzed results from 46 weight-loss diet studies with nearly 12,000 participants. They found average weight loss was 6% (approximately 10 or 15 pounds) among all diets or with...

  • Review: Orlistat and sibutramine are modestly effective for weight loss at 1 year. Padwal, R. // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p19 

    The article reports that orlistat and sibutramine are modestly effective for weight loss at one year. Studies of off-label therapy, drugs with high addiction potential that preclude long-term use or investigational, herbal or alternative compounds were excluded. Study quality assessment included...

  • NOT REALLY RANDOM.  // Nutrition Action Health Letter;Jan/Feb2005, Vol. 32 Issue 1, p9 

    Presents information on the results of several clinical studies conducted by John Zenk, chief medical and scientific director of Humanetics Corp., regarding the effects of taking the LeanSource weight-loss supplement and Fluidjoint dairy extract osteoarthritis pain reliever. Comparison of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics